Skip to main content
. 2022 Oct 9;14(10):694. doi: 10.3390/toxins14100694

Table 2.

Characteristics of envenomed patients who received antivenom and incidences of early adverse reactions.

Characteristics No. of Patients Receiving AV No. of Patients Receiving AV with EARs Incidence of
EARs (%)
Age in years: Median (IQR, range) 38 (21–55, 1–97) 35 (19–50, 1–87)
Gender ratio, Female:Male: N (%) 266:418 (38.9:61.1) 34.4:65.6 (53:101)
FREQUENCY OF AV USED PER PATIENT, Median (IQR, range):
Hematotoxic envenomation
   Total doses/patient
   Total vials/patient

1 (1–2, 1–15)
5 (3–9, 1–75)

2 (1–2.8, 1–6)
5.5 (3–9, 1–18)
Neurotoxic envenomation
   Total doses/patient
   Total vials/patient

1 (1–1, 1–4)
10 (10–10, 1–30)

1 (1–1, 1–4)
10 (10–10,1–24)
VENOMOUS SNAKES CATEGORIZED BY SYSTEMIC ENVENOMING, N (%):
Hematotoxic snakes: a 429 (62.7%) a 108 (70.1%) 25.2
   Green pit viper b 213 (31.1%) b 44 (28.6%) 20.7
   Malayan pit viper b 143 (20.9%) b 54 (35.1%) 37.8
   Russell’s viper b 28 (4.1%) b 2 (1.3%) 7.1
   Red-necked keelback 1 (0.1%) 0 0
   Mountain pit viper 1 (0.1%) 0 0
   Unknown hematotoxic snakes 43 (6.3%) 8 (5.2%) 18.6
Neurotoxic snakes: 255 (37.3%) 46 (29.9%) 18.0
   Cobra 188 (27.5%) 32 (20.8%) 17.0
   Malayan krait 20 (2.9%) 4 (2.6%) 20.0
   King cobra 7 (1.0%) 3 (1.9%) 42.9
   Coral snakes 0 0 0
   Banded krait 2 (0.3%) 1 (0.6%) 50.0
   Unknown neurotoxic snakes 38 (5.6%) 6 (3.9%) 15.8
Total 684 (100%) 154 (100%) 22.5
NUMBER OF TYPES OF ANTIVENOM THERAPY IN EACH PATIENT, N (%):
     * One 651 (95.2%) 145 (94.2%) 22.3
    ** Two 31 (4.5%) 9 (5.8%) 29.0
   *** Three 2 (0.3%) 0 0

AV; antivenom, EARs; early adverse reactions, N; number, IQR; interquartile range. * Only one specific antivenom was given, either monovalent or polyvalent antivenom. ** Two specific types of monovalent and/or polyvalent antivenoms were given. *** Three different types of specific monovalent and/or polyvalent antivenom were given. a p-value = 0.031, b p-value = 0.001.